全文获取类型
收费全文 | 3896篇 |
免费 | 441篇 |
国内免费 | 83篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 32篇 |
妇产科学 | 48篇 |
基础医学 | 450篇 |
口腔科学 | 141篇 |
临床医学 | 209篇 |
内科学 | 642篇 |
皮肤病学 | 50篇 |
神经病学 | 373篇 |
特种医学 | 119篇 |
外国民族医学 | 1篇 |
外科学 | 703篇 |
综合类 | 143篇 |
现状与发展 | 1篇 |
预防医学 | 96篇 |
眼科学 | 176篇 |
药学 | 157篇 |
1篇 | |
中国医学 | 40篇 |
肿瘤学 | 1024篇 |
出版年
2024年 | 23篇 |
2023年 | 103篇 |
2022年 | 190篇 |
2021年 | 258篇 |
2020年 | 214篇 |
2019年 | 197篇 |
2018年 | 195篇 |
2017年 | 192篇 |
2016年 | 194篇 |
2015年 | 240篇 |
2014年 | 302篇 |
2013年 | 285篇 |
2012年 | 170篇 |
2011年 | 204篇 |
2010年 | 132篇 |
2009年 | 170篇 |
2008年 | 167篇 |
2007年 | 155篇 |
2006年 | 143篇 |
2005年 | 106篇 |
2004年 | 82篇 |
2003年 | 94篇 |
2002年 | 83篇 |
2001年 | 82篇 |
2000年 | 52篇 |
1999年 | 30篇 |
1998年 | 50篇 |
1997年 | 46篇 |
1996年 | 32篇 |
1995年 | 35篇 |
1994年 | 40篇 |
1993年 | 31篇 |
1992年 | 20篇 |
1991年 | 15篇 |
1990年 | 18篇 |
1989年 | 12篇 |
1988年 | 6篇 |
1987年 | 11篇 |
1986年 | 4篇 |
1985年 | 6篇 |
1984年 | 6篇 |
1983年 | 9篇 |
1982年 | 7篇 |
1981年 | 4篇 |
1980年 | 2篇 |
1979年 | 1篇 |
1977年 | 1篇 |
1966年 | 1篇 |
排序方式: 共有4420条查询结果,搜索用时 14 毫秒
981.
982.
Mingzhi Hao ;Hailan Lin ;Youhong Shen ;Linan Tang ;Ruoyuan Yan ;Jianxiong Zheng ;Ojzhong Chen ;Jing Chen ;Zhougui Wu 《德国医学》2009,(2):69-72
Objective: To evaluate the efficacy of percutaneous ethanol injection (PEI) in the adjuvant treatment of hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE) by primary end points of time to progress (TTP). Methods: The study population consisted of 73 consecutive patients with inoperable HCC (China Classification System IIN liB). Among them, 22 patients were treated with TACE and PEI (experimental group), and the rest 51 were treated only with TACE (control group), and then the time to progress (TTP) and overall survival (OS) of these two groups were analyzed. Results: The median TTP was 10 months [95% confidence interval (CI), 7.9-12.1 months] in experimental group and 6 months (95% CI, 4.7-7.3 months) in control group. The 3-month,6-month, and 1-year Progression Free Survival (PFS) rates were respectively 77.3%, 63.6%, and 48.1% in experimental group, and 76.5%, 42.15%, and 24.8% in control group. The TTP of experimental group was significantly longer than that of control group (P 〈 0.05). The median survival period was 17 months [95% confidence interval (CI), 11-23 months] of experimental group and 12 months (95% CI, 10-14 months) of control group (P 〉 0.05). Conclusion: Compared with single TACE, the combination of TACE and PEI can obviously postpone disease progress and prolong survival of HCC patients. 相似文献
983.
Jaume Capdevila Enrique Grande Rocío García-Carbonero Marc Sim Mª Isabel del Olmo-García Paula Jimnez-Fonseca Alberto Carmona-Bayonas Virginia Pubul 《The oncologist》2022,27(4):e328
BackgroundThe aim of this study was to provide a guidance for the management of neuroendocrine tumors (NETs) in clinical practice.Material and MethodsNominal group and Delphi techniques were used. A steering committee of 8 experts reviewed the current management of NETs, identified controversies and gaps, critically analyzed the available evidence, and formulated several guiding statements for clinicians. Subsequently, a panel of 26 experts, was selected to test agreement with the statements through 2 Delphi rounds. Items were scored on a 4-point Likert scale from 1 = totally agree to 4 = totally disagree. The agreement was considered if ≥75% of answers pertained to Categories 1 and 2 (consensus with the agreement) or Categories 3 and 4 (consensus with the disagreement).ResultsOverall, 132 statements were proposed, which incorporated the following areas: (1) overarching principles; (2) progression and treatment response criteria; (3) advanced gastro-enteric NETs; (4) advanced pancreatic NETs; (5) advanced NETs in other locations; (6) re-treatment with radioligand therapy (RLT); (7) neoadjuvant therapy. After 2 Delphi rounds, only 4 statements lacked a clear consensus. RLT was not only recommended in the sequencing of different NETs but also as neoadjuvant treatment, while several indications for retreatment with RLT were also established.ConclusionThis document sought to pull together the experts’ attitudes when dealing with different clinical scenarios of patients suffering from NETs, with RLT having a specific role where evidence-based data are limited. 相似文献
984.
背景与目的:未经治疗的晚期贲门腺癌患者的生存时间为8~9个月.本研究目的是观察未进行任何治疗的早期胃贲门腺癌的自然发展史.方法:1987年在食管癌高发现场,对细胞学诊断为鳞状细胞重度增生的851例进行了内镜复查,同时检查了贲门区粘膜,经活检病理确诊为贲门腺癌者共43例.包括晚期癌12例,早期癌31例.其中17例早期患者虽经多次劝说,仍因不同原因拒绝治疗,随诊观察14年,直至全部患者死亡.结果:随诊14年,17例早期贲门癌患者中,12例死于贲门腺癌,另外5例死于非癌疾病;生存5年以上者13例,5年自然生存率为76.47%(13/17),10年自然生存率为23.53%(4/17).结论:早期贲门癌发展到晚期是一个漫长的演进过程.这对早期诊断和选择治疗时机很有帮助.同时,如要精确评估早期癌治疗效果,宜充分考虑其自然史的因素. 相似文献
985.
目的 探讨肺癌术后患者症状群对恐惧疾病进展水平的影响,为加强症状管理以减轻患者疾病恐惧感提供参考。方法 以便利抽样法选取228例原发性肺癌手术患者,采用一般资料问卷、恐惧疾病进展简化量表(FoP-Q-SF)、中文版安德森症状评估量表-肺癌特异性症状模块(MDASI-L)进行调查。结果 肺癌术后患者的恐惧疾病进展总分为(29.75±9.10)分,症状发生率前3位分别为疲乏(98.25%)、疼痛(97.81%)和咳嗽(95.61%),症状严重程度分别为疼痛[5.00(3.00,8.00)]、疲乏[5.00(3.00,7.00)]和睡眠不安[5.00(2.00,7.00)]。探索性因子分析得出3个症状群,分别为疾病行为-心理情感症状群、肺癌特异症状群、胃肠道-神经症状群。Spearman相关性分析结果显示,恐惧疾病进展总分及各维度得分与3个症状群呈正相关(rs=0.467~0.683,均P<0.05)。多元线性回归分析显示,疾病行为-心理情感症状群、肺癌特异症状群为患者恐惧疾病进展的影响因素(均P<0.05)。结论 肺癌术后患者存在多种症状群,症状群越严重,患者的恐惧疾病进展水平越高,提示医护人员应做好肺癌术后患者症状群管理,以减轻患者对自身疾病进展或复发的恐惧心理,进而改善其生活质量。 相似文献
986.
Jintao Ma Chunliu Meng Jia Tian Kai Ren Huijun Jia Meng Yan Liming Xu Lujun Zhao 《Current oncology (Toronto, Ont.)》2022,29(10):7979
Purpose: The purpose of this study was to investigate the prognostic differences between patients with small-cell lung cancer (SCLC) with different chemosensitivity to first-line chemotherapy who developed brain metastasis (BM) as the first site of progression. Methods: Patients with a BM after first-line treatment in the Tianjin Cancer Hospital were retrospectively analyzed. According to the time-free interval (TFI) between the completion of first-line chemotherapy and the onset of the BM, the patients were divided into the chemo-sensitive group (TFI ≥ 90 days, n = 145) and the chemo-resistant group (TFI < 90 days, n = 97). The survival time, which was calculated from the diagnosis of the BM, was analyzed after the onset of brain metastasis (BM-OS). Survival curves were plotted using the Kaplan–Meier method, and differences between groups were compared using the log-rank test. Results: In total, the median BM-OS was 8.4 months. The median BM-OS in the chemo-sensitive group was 8.8 months, and it was 8.0 months in the chemo-resistant group (p = 0.538). In patients without extracranial progression (n = 193), the median BM-OSes in the chemo-sensitive and chemo-resistant groups were 9.4 months and 9.7 months, respectively (p = 0.947). In patients with extracranial progression (n = 49), the median BM-OSes in the chemo-sensitive and chemo-resistant groups were 5.4 months and 4.2 months, respectively (p = 0.161). Conclusions: After the development of a BM as the first site of progression following chemotherapy in patients with SCLC, the prognosis of chemo-sensitive patients was not necessarily superior to chemo-resistant patients, especially in patients without extracranial progression. 相似文献
987.
Yanzhuang Ke Jieying Mai Zhendong Liu Yuyang Xu Chunyi Zhao Baochun Wang 《Journal of gastrointestinal oncology.》2022,13(5):2197
BackgroundCancer-associated fibroblasts (CAFs) are vital components of gastric cancer (GC) microenvironments, which impact the aggressive characteristics of GC cells. The objective of this study is to evaluate the influence of High Mobility Group Box (HMGB) on CAF-related GC.MethodsThe tissues of 10 GC patients who underwent surgery the Sanya Central Hospital of Hainan Province from July 2018 to July 2019 were collected for the clinical study. Moreover, the GC cell lines, including MGC-803, AGS, and SGC-7901, were used in vitro experiment. We investigated the molecular mechanism of the miR-200b/HMGB3 axis in affecting the chemoresistance and epithelial-mesenchymal transition (EMT) of GC cells induced by CAFs. Cell transfection, Cell Counting Kit-8 (CCK-8), Transwell assay, western blot, enzyme-linked immunosorbent assay (ELISA), and other experiments were employed.ResultsWe found that miR-200b was down-regulated, yet HMGB3 was up-regulated in CAF-related GC. The CAFs markedly promoted cisplatin (CDDP) resistance, proliferation, invasion, migration, and EMT of GC cells. Gain-assay of miR-200b demonstrated that miR-200b inhibited the HMGB3 release from CAFs. In-vivo experiments confirmed that the growth and EMT of GC cells co-cultured with CAF-miR-200b were significantly reduced. Furthermore, CAFs enhanced the activation of ERK, JNK, and the Wnt/β-catenin pathways, and those pathways, as well as the malignant behaviors of GC cells, were obviously attenuated by miR-200b or HMGB3 silencing.ConclusionsCollectively, HMGB3 derived from CAFs is negatively regulated by miR-200b and promotes the malignant behaviors of GC cells. 相似文献
988.
989.
Xiaoqin Lai Wenfa Chen Yuzhu Wu Yali Gao Yalan Zhang Xuwei Xu Ya Fu Xinwen Wang Yanbing Yang Yin Zhang 《Journal of clinical laboratory analysis》2022,36(7)
It was known that mutations in the RT region were mainly related to nucleot(s)ide analogs resistance. Increasing studies indicated that RT mutations were related to advanced liver diseases (ALD) and had effects on HBV replication, but the distribution characteristics of mutations across RT region in the development of liver diseases and the effect of RT mutations on HBV replication were not fully clarified. HBV RT region was direct‐sequenced in 1473 chronic HBV‐infected patients. Mutation frequencies were analyzed to identify the specific mutations differing between groups classified by genotypes, loads of HBV DNA, or progression of liver diseases. In the range of rt145‐rt290, rt145, rt221, rt222, rt267, and rt271 were the genotype‐polymorphic sites, while rt238 was the genotype‐specific sites. Mutations at rt163, rt173, rt180, rt181, rt184, rt191, rt199, and rt214 were more frequent among patients with C‐genotype HBV, while those at rt220, rt225, rt226, rt269, and rt274 were more frequent among patients with B‐genotype HBV. RtM204V/I could reduce the HBV DNA loads while rtQ/L267H/R could increase the HBV DNA loads. RtV214A/E/I (OR 3.94, 95% CI 1.09 to 14.26) was an independent risk factor for advanced liver diseases. In summary, the hotspots of mutations were different between B and C genotypes. Besides the effect on the S region, RT mutations had effects on HBV replication by other unknown ways. RtV214A/E/I was found to be an independent risk factor for ALD, suggesting that mutations at rt214 site could be used as a potential virological marker for the liver disease progression. 相似文献
990.
Zhi-Yun Zhang Zhi-Yuan Ouyang Guo-Hua Zhao Jia-Jia Fang 《World Journal of Clinical Cases》2022,10(19):6664
BACKGROUNDMills’ syndrome is an extremely rare degenerative motor neuron disorder first described by Mills in 1900, but its nosological status is still not clear. We aimed to analyze the clinical features of Mills’ syndrome.CASE SUMMARYHerein, we present 3 cases with similar features as those described in Mills’ original paper and review the related literature. Our patients showed middle- and older-age onset, with only upper motor neuron symptoms evident throughout the course of the disease. Spastic hemiplegia began in the lower extremity with a unique progressive pattern.CONCLUSIONWe consider that Mills’ syndrome is a unique entity of motor neuron disorder with an N-shaped progression. Clinicians should maintain a high index of suspicion for the diagnosis of Mills’ syndrome when the onset involves lower extremity paralysis without evidence of lower motor neuron or sensory involvement. 相似文献